EXExelixis EXEL · NASDAQ
$66.20 -0.12% (-$0.08)
- Market cap
- $16.6B
- Enterprise value
- $16.5B
- P/E
- 19.3x
- Forward P/E
- 20.5x
- PEG
- 0.4x
- P/S
- 6.8x
- P/FCF
- 14.1x
- EV/EBITDA
- 15.9x
- ROIC
- 37.9%
- Gross margin
- 96.5%
- Net margin
- 35.3%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -0.1x
- Beta
- 0.42
- Free float
- 85.0%
About the company
Exelixis, Inc. is an American biotechnology company focused on the development and commercialization of innovative therapies in the field of oncology. The company concentrates on the research and development of new therapeutic options for the treatment of various types of cancer, including liver, lung, and kidney cancer. Exelixis is known for its main drug, cabozantinib, which is used to treat several cancer types. The company collaborates with other biotechnology and pharmaceutical firms to develop new drugs and therapies.
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Morrissey
Employees
1,077
Headquarters
Alameda
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Earnings per share grew by 71% a year over the last 3 years.
- What to watch: Earnings per share swing sharply from year to year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 35 USD is left as net profit.
- What speaks for it: It earns 38 USD a year on every 100 USD of invested capital.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $304.8M against $162.2M.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number